N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Laparoscopic Surgery
Conditions
Laparoscopic Surgery
Trial Timeline
Oct 1, 2011 → Mar 1, 2012
NCT ID
NCT01436032About N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo
N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo is a phase 3 stage product being developed by Alkermes for Laparoscopic Surgery. The current trial status is terminated. This product is registered under clinical trial identifier NCT01436032. Target conditions include Laparoscopic Surgery.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01436032 | Phase 3 | Terminated |
Competing Products
7 competing products in Laparoscopic Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pudexacianinium chloride | Astellas Pharma | Phase 2 | 52 |
| SHR0410 Injection + SHR0410 Injection + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Rocuronium + Rocuronium | Merck | Approved | 85 |
| Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2 | Merck | Approved | 85 |
| etoricoxib 120 mg | Merck | Approved | 85 |
| placebo + valdecoxib + valdecoxib | Pfizer | Phase 3 | 76 |